Clinical Trials Logo

Leptomeningeal Carcinomatosis clinical trials

View clinical trials related to Leptomeningeal Carcinomatosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT03613181 Not yet recruiting - Brain Metastases Clinical Trials

ANG1005 in Leptomeningeal Disease From Breast Cancer

ANGLeD
Start date: December 2023
Phase: Phase 3
Study type: Interventional

This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.

NCT ID: NCT02939300 Completed - Clinical trials for Leptomeningeal Carcinomatosis

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Start date: February 15, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases. The names of the study interventions involved in this study are: - Ipilimumab - Nivolumab

NCT ID: NCT02755987 No longer available - Clinical trials for Anaplastic Astrocytoma

Expanded Access to ANG1005 for Individual Patients

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient from Protocol ANG1005-CLN-04 with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.

NCT ID: NCT00830245 Terminated - Clinical trials for Non-small Cell Lung Cancer

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

Start date: January 2009
Phase: Phase 2
Study type: Interventional

To assess the efficacy and safety of erlotinib for non-small cell lung cancer patients with leptomeningeal carcinomatosis

NCT ID: NCT00527410 Terminated - Clinical trials for Leptomeningeal Carcinomatosis

A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis

LMD
Start date: October 31, 2006
Phase: Phase 1
Study type: Interventional

This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent neoplastic meningitis.